Le Lézard
Classified in: Health, Science and technology, Business
Subjects: STOCK/OTHER MARKET NEWS, ANNUAL MEETINGS

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders


TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27, 2019. The results of the director elections were as follows:

          
  Votes in Favor % Votes in Votes % Votes 
 Name  Favor Withheld Withheld 
 Mr. Luke Beshar5,579,317 85 977,217 15 
 Dr. Robert Kirkman5,614,544 85 941,990 15 
 Dr. Michael Moore5,586,552 85 969,982 15 
 Dr. Thomas Reynolds5,580,252 85 976,282 15 
 Dr. Robert Uger5,615,550 86 940,984 14 
 Dr. Calvin Stiller5,581,832 85 974,702 15 
 Dr. Helen Tayton-Martin5,687,094 87 869,440 13 
          

The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the special resolutions to continue the Corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act and the potential consolidation of the Corporation's issued and outstanding common shares.

About Trillium Therapeutics:

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com 

Investor Relations:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com


These press releases may also interest you

15 jan 2021
Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") and certain of its officers. The class action, filed in United States District Court for the...

15 jan 2021
LONDON, Jan. 16, 2021 PRNewswire/-- A limited time offer operating under St Kitts and Nevis' Citizenship by Investment (CBI) Programme has now expired. Introduced late last year, the temporary discount enabled families of up to four to acquire...

15 jan 2021
TSX VENTURE COMPANIES CABO DRILLING CORP. ("CBE.H")[formerly Cabo Drilling Corp. ("CBE")BULLETIN TYPE:  Transfer and New Addition to NEX, Symbol Change, Remain SuspendedBULLETIN DATE:  January 15, 2021TSX Venture Tier 2 Company In accordance with TSX...

15 jan 2021
Unifor Local 88's bargaining committee, representing 1,900 workers at the CAMI Assembly Plant in Ingersoll, Ontario has reached a tentative agreement with General Motors today....

15 jan 2021
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

15 jan 2021
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...



News published on 2 july 2019 at 07:05 and distributed by: